Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$423.33 USD

423.33
207,247

+5.48 (1.31%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $424.08 +0.75 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Chemed (CHE) Up 8.3% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold on to Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

Aparajita Dutta headshot

Silver Tsunami to Hit the United States: 4 Stocks in Focus

by Aparajita Dutta

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Zacks Equity Research

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CHE) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

What Makes Chemed (CHE) a New Buy Stock

by Zacks Equity Research

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.

Zacks Equity Research

Chemed (CHE) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 2.22% and -1.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Chemed (CHE) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CHE) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.

Zacks Equity Research

Stryker (SYK) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.

Zacks Equity Research

Why Chemed (CHE) Might Surprise This Earnings Season

by Zacks Equity Research

Chemed (CHE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

What's in Store for Juniper (JNPR) This Earnings Season?

by Zacks Equity Research

Juniper's (JNPR) first-quarter 2020 performance is likely to have benefited from changes to its go-to-market structure to better align sales strategies with each of the core customer verticals.

Zacks Equity Research

Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings

by Zacks Equity Research

Headwinds in the Optical Communications and Display Technologies business segments are likely to get reflected in Corning's (GLW) first-quarter 2020 results.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group

Zacks Equity Research

Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View

by Zacks Equity Research

Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.

Zacks Equity Research

Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1

Zacks Equity Research

ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

ABIOMED's (ABMD) fiscal fourth-quarter performance is likely to reflect growth in Impella product line.

Zacks Equity Research

Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.

Nalak Das headshot

5 Top Growth Stocks to Buy Ahead of Q1 Earnings This Month

by Nalak Das

Five growth stocks with a favorable Zacks Rank that are set to beat first-quarter earnings estimates this month.

Zacks Equity Research

Cerner (CERN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.

Zacks Equity Research

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.

Zacks Equity Research

3 Reasons Why Chemed (CHE) Is a Great Growth Stock

by Zacks Equity Research

Chemed (CHE) could produce exceptional returns because of its solid growth attributes.